title: [First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion") - AN 37/15 der AUO].
authors.affiliation: Geschäftsstelle der AUO, Seestr. 11, 17252, Schwarz, Deutschland. auo.presse@MeckEvidence.de.
authors.forename: H
authors.initials: H
authors.lastname: Rexer
authors.affiliation: Urologikum Lübeck, Lübeck, Deutschland.
authors.forename: C
authors.initials: C
authors.lastname: Doehn
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology*; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D005858:Germany; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011758:Pyrroles / Q000008:administration & dosage*; D012107:Research Design; D000077210:Sunitinib; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007211:Indoles; D011758:Pyrroles; D000068258:Bevacizumab; C000594389:atezolizumab; D000077210:Sunitinib